Morgan Stanley Reiterates Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $340
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $305 to $340.
July 03, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Vertex Pharmaceuticals and raised the price target from $305 to $340.
The raised price target by Morgan Stanley indicates a positive outlook for Vertex Pharmaceuticals. This could potentially lead to an increase in the stock price in the short term as it signals the analyst's increased confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100